A Meta-analysis and Systematic Review Evaluating the Use of Erythropoietin in Total Hip and Knee Arthroplasty

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2018 Jul 20

PMID 30022832

Citations 9

Authors

Yi Li

Pengbin Yin

Houchen Lv

Yutong Meng

Licheng Zhang

Peifu Tang

Affiliations

Soon will be listed here.

Abstract

Purpose: The debate is still ongoing on the effectiveness and safety of erythropoietin (EPO) treatment in orthopedic surgeries. Specifically, previous studies have not compared the dynamic change of hemoglobin (Hb) levels between different transfusion methods. Besides, complications or side effects of this alternative have not been quantitatively analyzed. We conducted a meta-analysis and systemic review to evaluate the efficacy of EPO on Hb levels observed during the whole perioperative period as well as the volume of allogeneic blood transfusion (ABT), the risk of venous thromboembolism, and application frequency of ABT in hip and knee surgery.

Materials And Methods: PubMed, Embase, Web of Science, and the Cochrane library were systematically searched from inception to November 2017. The data from randomized controlled trials were extracted and the risk of bias assessed using Cochrane's Collaboration's tool.

Results: Twenty-five randomized controlled trials involving 4,159 patients were included in this meta-analysis. EPO could reduce exposure to allogeneic blood transfused (odds ratio [OR] =0.42, =0.001) and reduce the average volume of allogeneic blood transfused (OR = -0.28, =0.002). When EPO and preoperative autologous blood donation (PABD) were compared, the use of EPO was associated with lower exposure to ABT (OR =0.48, =0.03), but no significant decrease in the average volume of allogeneic blood transfused (OR = -0.23, =0.32). The use of EPO was associated with a higher level of Hb with or without use of PABD at all the 4 time points (preoperation, 24-48 hours postoperation, 3-5 days postoperation, discharge of last observation) (<0.0001), which means EPO could increase the level of Hb significantly during the perioperative period. The results also indicated EPO does not increase the risk of a venous thromboembolism event.

Conclusion: Preoperative administration of EPO was shown to generally increase Hb levels during the whole perioperative period; however, the extent of the positive effects varies with time points. Additionally, EPO minimizes the need for transfusion significantly in patients undergoing hip or knee surgery without increasing the chance of developing thrombotic complications. Therefore, EPO offers an alternative blood management strategy in total hip arthroplasty and total knee arthroplasty.

Citing Articles

[Diagnosis and treatment of perioperative anaemia in elective primary hip and knee arthroplasty : Consensus statement of the "Committee for Perioperative Management" of the Working Group for Endoprosthetics].

Reinke J, Meybohm P, Weber P Orthopadie (Heidelb). 2025; 54(2):115-121.

PMID: 39833316 DOI: 10.1007/s00132-024-04602-7.

Effect of intraoperative intravenous ferric derisomaltose supplementation on reduction of postoperative anemia and transfusion in chronic kidney disease patients after total knee replacement.

Kwon J, Cho Y, Jang W, Kim S, Ko H, Ko W Medicine (Baltimore). 2022; 101(35):e30105.

PMID: 36107525 PMC: 9439733. DOI: 10.1097/MD.0000000000030274.

EFFICACY OF EXTENDED ORAL TRANEXAMIC ACID ON BLOOD LOSS IN PRIMARY TOTAL KNEE ARTHROPLASTY.

Yuenyongviwat V, Dissaneewate K, Iamthanaporn K, Tuntarattanapong P, Hongnaparak T Acta Ortop Bras. 2022; 30(spe1):e247197.

PMID: 35864836 PMC: 9270054. DOI: 10.1590/1413-785220223001e247197.

Intravenous Ferric Carboxymaltose Improves Response to Postoperative Anemia Following Total Knee Arthroplasty: A Prospective Randomized Controlled Trial in Asian Cohort.

Choi K, Koh I, Kim M, Kim C, In Y J Clin Med. 2022; 11(9).

PMID: 35566482 PMC: 9103711. DOI: 10.3390/jcm11092357.

Total Hip Replacement for Osteoarthritis-Evidence-Based and Patient-Oriented Indications.

Gunther K, Deckert S, Lutzner C, Lange T, Schmitt J, Postler A Dtsch Arztebl Int. 2021; 118(43):730-736.

PMID: 34693905 PMC: 8820083. DOI: 10.3238/arztebl.m2021.0323.

References

Zhao Y, Jiang C, Peng H, Feng B, Li Y, Weng X . The effectiveness and safety of preoperative use of erythropoietin in patients scheduled for total hip or knee arthroplasty: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95(27):e4122. PMC: 5058850. DOI: 10.1097/MD.0000000000004122. View

Voorn V, van der Hout A, So-Osman C, Vlieland T, Nelissen R, van den Akker-van Marle M . Erythropoietin to reduce allogeneic red blood cell transfusion in patients undergoing total hip or knee arthroplasty. Vox Sang. 2016; 111(3):219-225. DOI: 10.1111/vox.12412. View

Wurnig C, Schatz K, Noske H, Hemon Y, DAHLBERG G, Josefsson G . Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res. 2002; 33(5-6):303-10. DOI: 10.1159/000049723. View

Elliott S, Tomita D, Endre Z . Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol. 2017; 18(1):14. PMC: 5225567. DOI: 10.1186/s12882-017-0438-4. View

Beris P, Mermillod B, Levy G, Laubriat M, Tullen E, Hugli A . Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sang. 1993; 65(3):212-8. DOI: 10.1111/j.1423-0410.1993.tb02152.x. View

Deutsch A, Spaulding J, Marcus R . Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty. J Arthroplasty. 2006; 21(5):628-35. DOI: 10.1016/j.arth.2005.12.002. View

Gonzalez-Porras J, Colado E, Conde M, Lopez T, Nieto M, Corral M . An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med. 2009; 19(1):35-42. DOI: 10.1111/j.1365-3148.2009.00908.x. View

Yamanaka K, Eldeiry M, Aftab M, Mares J, Ryan T, Meng X . Optimized induction of beta common receptor enhances the neuroprotective function of erythropoietin in spinal cord ischemic injury. J Thorac Cardiovasc Surg. 2018; 155(6):2505-2516. DOI: 10.1016/j.jtcvs.2017.12.132. View

Buljan M, Nemet D, Golubic-Cepulic B, Bicanic G, Tripkovic B, Delimar D . Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. Int Orthop. 2011; 36(4):703-9. PMC: 3311821. DOI: 10.1007/s00264-011-1367-7. View

10.

Hill G, Frawley W, Griffith K, Forestner J, Minei J . Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma. 2003; 54(5):908-14. DOI: 10.1097/01.TA.0000022460.21283.53. View

11.

Anderson Jr F, Spencer F . Risk factors for venous thromboembolism. Circulation. 2003; 107(23 Suppl 1):I9-16. DOI: 10.1161/01.CIR.0000078469.07362.E6. View

12.

Jorgensen C, Kehlet H . Early thromboembolic events ≤1week after fast-track total hip and knee arthroplasty. Thromb Res. 2016; 138:37-42. DOI: 10.1016/j.thromres.2015.12.025. View

13.

Avall A, Hyllner M, Bengtson J, Carlsson L, Bengtsson A . Recombinant human erythropoietin in preoperative autologous blood donation did not influence the haemoglobin recovery after surgery. Acta Anaesthesiol Scand. 2003; 47(6):687-92. DOI: 10.1034/j.1399-6576.2003.00130.x. View

14.

Price T, Goodnough L, VOGLER W, Sacher R, Hellman R, Johnston M . The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion. 1996; 36(1):29-36. DOI: 10.1046/j.1537-2995.1996.36196190512.x. View

15.

Keating E, Ritter M . Transfusion options in total joint arthroplasty. J Arthroplasty. 2002; 17(4 Suppl 1):125-8. DOI: 10.1054/arth.2002.32459. View

16.

Goodnough L, Price T, Friedman K, Johnston M, Ciavarella D, Khan N . A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion. 1994; 34(1):66-71. DOI: 10.1046/j.1537-2995.1994.34194098608.x. View

17.

Aksoy M, Tokgozoglu A . Erythropoietin for autologous blood donation in total hip arthroplasty patients. Arch Orthop Trauma Surg. 2001; 121(3):162-5. DOI: 10.1007/s004020000197. View

18.

Keating E, Callaghan J, Ranawat A, Bhirangi K, Ranawat C . A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: effect on postoperative vigor and handgrip strength. J Arthroplasty. 2007; 22(3):325-33. DOI: 10.1016/j.arth.2006.11.002. View

19.

Stivelman J . Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn). Semin Dial. 2017; 30(2):142-148. DOI: 10.1111/sdi.12569. View

20.

Jans O, Jorgensen C, Kehlet H, Johansson P . Role of preoperative anemia for risk of transfusion and postoperative morbidity in fast-track hip and knee arthroplasty. Transfusion. 2013; 54(3):717-26. DOI: 10.1111/trf.12332. View